CD133 in breast cancer cells and in breast cancer stem cells as another target for immunotherapy

Luis Tume; Karen Paco; Roberto Ubidia-Incio; Jeel Moya

doi:10.1016/j.gamo.2016.01.003

CD133 in breast cancer cells and in breast cancer stem cells as another target for immunotherapy

Luis Tume
, Karen Paco
, Roberto Ubidia-Incio
, Jeel Moya

Universidad Nacional de Piura
Universidad Peruana Cayetano Heredia

Producción científica: Contribución a una revista › Artículo de revisión › revisión exhaustiva

23 Citas (Scopus)

Resumen

Breast cancer consists of a heterogeneous group of tumors with different features, biology and treatments. Cancer stem cells (CSCs) have been associated with an aggressive cellular behavior, resistance to chemotherapy and radiotherapy in many types of neoplasms, and a strong correlation between prominin-1 (CD133) expression in cancer stem cells from different types of cancer exist. A discussion is presented on recent immunotherapeutic strategies that target CD133 in breast CSCs. Furthermore, it is suggested that immunotherapy targeting CD133 breast CSCs and/or in combination with other current treatments result in a better outcome.

Idioma original	Inglés
Páginas (desde-hasta)	22-30
Número de páginas	9
Publicación	Gaceta Mexicana de Oncologia
Volumen	15
N.º	1
DOI	https://doi.org/10.1016/j.gamo.2016.01.003
Estado	Publicada - 1 ene. 2016
Publicado de forma externa	Sí

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

ODS 3: Salud y bienestar

Acceder al documento

10.1016/j.gamo.2016.01.003

Otros archivos y enlaces

Enlace a la publicación en Scopus

Citar esto

@article{ce58793273fd4c9ebeabd1940e8418c8,

title = "CD133 in breast cancer cells and in breast cancer stem cells as another target for immunotherapy",

abstract = "Breast cancer consists of a heterogeneous group of tumors with different features, biology and treatments. Cancer stem cells (CSCs) have been associated with an aggressive cellular behavior, resistance to chemotherapy and radiotherapy in many types of neoplasms, and a strong correlation between prominin-1 (CD133) expression in cancer stem cells from different types of cancer exist. A discussion is presented on recent immunotherapeutic strategies that target CD133 in breast CSCs. Furthermore, it is suggested that immunotherapy targeting CD133 breast CSCs and/or in combination with other current treatments result in a better outcome.",

keywords = "Breast cancer, CD133, CSCs, Immunotherapy",

author = "Luis Tume and Karen Paco and Roberto Ubidia-Incio and Jeel Moya",

note = "Publisher Copyright: {\textcopyright} 2016 Sociedad Mexicana de Oncolog{\'i}a.",

year = "2016",

month = jan,

day = "1",

doi = "10.1016/j.gamo.2016.01.003",

language = "English",

volume = "15",

pages = "22--30",

journal = "Gaceta Mexicana de Oncologia",

issn = "1665-9201",

number = "1",

}

TY - JOUR

T1 - CD133 in breast cancer cells and in breast cancer stem cells as another target for immunotherapy

AU - Tume, Luis

AU - Paco, Karen

AU - Ubidia-Incio, Roberto

AU - Moya, Jeel

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Breast cancer consists of a heterogeneous group of tumors with different features, biology and treatments. Cancer stem cells (CSCs) have been associated with an aggressive cellular behavior, resistance to chemotherapy and radiotherapy in many types of neoplasms, and a strong correlation between prominin-1 (CD133) expression in cancer stem cells from different types of cancer exist. A discussion is presented on recent immunotherapeutic strategies that target CD133 in breast CSCs. Furthermore, it is suggested that immunotherapy targeting CD133 breast CSCs and/or in combination with other current treatments result in a better outcome.

AB - Breast cancer consists of a heterogeneous group of tumors with different features, biology and treatments. Cancer stem cells (CSCs) have been associated with an aggressive cellular behavior, resistance to chemotherapy and radiotherapy in many types of neoplasms, and a strong correlation between prominin-1 (CD133) expression in cancer stem cells from different types of cancer exist. A discussion is presented on recent immunotherapeutic strategies that target CD133 in breast CSCs. Furthermore, it is suggested that immunotherapy targeting CD133 breast CSCs and/or in combination with other current treatments result in a better outcome.

KW - Breast cancer

KW - CD133

KW - CSCs

KW - Immunotherapy

UR - https://www.scopus.com/pages/publications/84963596865

U2 - 10.1016/j.gamo.2016.01.003

DO - 10.1016/j.gamo.2016.01.003

M3 - Review article

AN - SCOPUS:84963596865

SN - 1665-9201

VL - 15

SP - 22

EP - 30

JO - Gaceta Mexicana de Oncologia

JF - Gaceta Mexicana de Oncologia

IS - 1

ER -

CD133 in breast cancer cells and in breast cancer stem cells as another target for immunotherapy

Resumen

ODS de las Naciones Unidas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto